Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RAPID: Early impact therapy with ceftazidime-avibactam via rapid diagnostics vs standard care in Pseudomonas aeruginosa or carbapenemase-producing Enterobacterales infections
KCT0009822Phase 4Not yet recruiting
- Sponsor
- National University of Singapore
- Start
- Dec 2024
- Modality
- Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of ceftazidime + avibactam in bloodstream infection (BSI), hospital-acquired pneumonia (HAP), ventilator-associated pneumonia (VAP), Pseudomonal infection, Enterobacterales infection, sponsored by National University of Singapore. Planned start Dec 2024; status: not yet recruiting.
02
Drugs
ceftazidime + avibactam
03
Conditions
bloodstream infection (BSI)hospital-acquired pneumonia (HAP)ventilator-associated pneumonia (VAP)Pseudomonal infectionEnterobacterales infection
Beyond the preview
Go deeper on KCT0009822.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0009822.